Investigation of the pharmacokinetics of 3′-deoxy-3′-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer☆
Abstract
Introduction
The kinetics of the bone marrow uptake of 3′-deoxy-3′-[18F]fluorothymidine (FLT) before and early after initiation of chemoradiation therapy was investigated in patients with head and neck cancer.
Methods
Fourteen subjects with head and neck cancer underwent FLT positron emission tomography (PET) at baseline and after 10 Gy of radiation therapy. Thirteen subjects also received one cycle of platinum-based chemotherapy before the second FLT PET. Kinetic parameters, including the flux constant based on compartmental analysis (KFLT) and the Patlak constant (KPatlak) for cervical marrow, were calculated. Standardized uptake values (SUVs) for the cervical marrow (inside the radiation field) and lumbar spine marrow (outside the radiation field) were also determined.
Results
There was a significant drop in FLT uptake in the bone marrow inside the radiation field. Mean pretreatment uptake values for the cervical spine were SUV=3.08±0.66, KFLT=0.045±0.016 min−1 and KPatlak=0.039±0.013 min−1. After treatment, these values were SUV=0.74±0.19, KFLT=0.011±0.005 min−1 and KPatlak=0.005±0.002 min−1. Compartmental analysis revealed a significant drop in k3 in irradiated cervical marrow. FLT uptake in the bone marrow outside the radiation field exhibited a significantly smaller decrease.
Conclusions
There is a marked decrease in FLT uptake in irradiated bone marrow after 10 Gy of radiation therapy to the head and neck. The drop in FLT uptake in irradiated marrow is due to a significant decrease in the net phosphorylation rate of FLT.
Keywords: 3′-Deoxy-3′-[18F]fluorothymidine, FLT, Bone marrow, Chemoradiation
To access this article, please choose from the options below
☆ Part of this study was presented at the Academy of Molecular Imaging/Society for Molecular Imaging Joint Molecular Imaging Conference 2007 in Providence, RI, and at the Society of Nuclear Medicine 2009 Annual Meeting in Toronto, Ontario, Canada.
PII: S0969-8051(10)00030-2
doi:10.1016/j.nucmedbio.2010.02.005
© 2010 Elsevier Inc. All rights reserved.
